Patents by Inventor Philip A. Band
Philip A. Band has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11897921Abstract: The present invention is directed to a fusion protein comprising a light chain region of a Clostridial neurotoxin and a heavy chain region of a Clostridial neurotoxin, where the light and heavy chain regions are linked by a disulfide bond. The fusion protein also has a single chain antibody positioned upstream of the light chain region, where the single chain antibody possesses antigen-binding activity. Also disclosed are therapeutic agents, treatment methods, propeptide fusions, isolated nucleic acid molecules, expression systems, host cells, and methods of expressing fusion proteins.Type: GrantFiled: December 9, 2015Date of Patent: February 13, 2024Assignee: NEW YORK UNIVERSITYInventors: Konstantin Ichtchenko, Edwin Vazquez-Cintron, Philip A. Band, Timothy J. Cardozo
-
Publication number: 20220333091Abstract: Described herein are recombinant Clostridium botulinum neurotoxins comprising a light chain of a Clostridium botulinum neurotoxin, wherein the light chain comprises a mutation that causes minimal structural interference to the light chain protease; a heavy chain of a Clostridium botulinum neurotoxin, wherein the light and heavy chains are linked by a disulfide bond. The recombinant Clostridium botulinum neurotoxin has a 2-20 fold reduced toxicity compared to wild type Clostridium botulinum neurotoxin. Also described is a treatment method.Type: ApplicationFiled: September 30, 2020Publication date: October 20, 2022Inventors: Konstantin ICHTCHENKO, Philip A. BAND
-
Patent number: 9939450Abstract: This invention relates to a method of predicting progression of an inflammatory condition in a subject, which involves providing a medium comprising hyaluronan or a fragment thereof; contacting the medium with a fluid sample from a subject with an inflammatory condition, where the fluid sample comprises proteins or proteoglycans and a transfer agent; incubating the fluid sample with the medium under conditions effective for the transfer agent in the fluid sample to mediate transfer of heavy chains from the proteins or proteoglycans to the hyaluronan or a fragment thereof to form a complex; detecting, using an antibody, occurrence levels of the complex; and comparing occurrence levels of the complex from said detecting to a reference standard to predict progression of an inflammatory condition in the subject. Also disclosed are methods of tailoring treatment of an inflammatory condition and quantifying local inflammatory activity in a body fluid.Type: GrantFiled: November 10, 2014Date of Patent: April 10, 2018Assignees: New York University, Duke University Medical CenterInventors: Philip A. Band, Hans-Georg Wisniewski, Virginia Byers Kraus
-
Publication number: 20160296608Abstract: The present invention relates to a treatment method. This method involves contacting a subject with an isolated, physiologically active, atoxic derivative of a Clostridial neurotoxin. Contacting is carried out to treat the subject. The derivative of a Clostridial neurotoxin does not possess a cargo attachment peptide sequence at its N-terminus.Type: ApplicationFiled: April 15, 2016Publication date: October 13, 2016Applicant: New York UniversityInventors: Edwin J. Vazquez-Cintron, Konstantin Ichtchenko, Philip A. Band
-
Publication number: 20160159866Abstract: The present invention is directed to a fusion protein comprising a light chain region of a Clostridial neurotoxin and a heavy chain region of a Clostridial neurotoxin, where the light and heavy chain regions are linked by a disulfide bond. The fusion protein also has a single chain antibody positioned upstream of the light chain region, where the single chain antibody possesses antigen-binding activity. Also disclosed are therapeutic agents, treatment methods, propeptide fusions, isolated nucleic acid molecules, expression systems, host cells, and methods of expressing fusion proteins.Type: ApplicationFiled: December 9, 2015Publication date: June 9, 2016Applicant: New York UniversityInventors: Konstantin Ichtchenko, Edwin Vazquez-Cintron, Philip A. Band, Timothy J. Cardozo
-
Patent number: 9315549Abstract: The present invention relates to a treatment method. This method involves contacting a subject with an isolated, physiologically active, atoxic derivative of a Clostridial neurotoxin. Contacting is carried out to treat the subject. The derivative of a Clostridial neurotoxin does not possess a cargo attachment peptide sequence at its N-terminus.Type: GrantFiled: January 28, 2014Date of Patent: April 19, 2016Assignee: New York UniversityInventors: Edwin J. Vazquez-Cintron, Konstantin Ichtchenko, Philip A. Band
-
Publication number: 20150204888Abstract: This invention relates to a method of predicting progression of an inflammatory condition in a subject, which involves providing a medium comprising hyaluronan or a fragment thereof; contacting the medium with a fluid sample from a subject with an inflammatory condition, where the fluid sample comprises proteins or proteoglycans and a transfer agent; incubating the fluid sample with the medium under conditions effective for the transfer agent in the fluid sample to mediate transfer of heavy chains from the proteins or proteoglycans to the hyaluronan or a fragment thereof to form a complex; detecting, using an antibody, occurrence levels of the complex; and comparing occurrence levels of the complex from said detecting to a reference standard to predict progression of an inflammatory condition in the subject. Also disclosed are methods of tailoring treatment of an inflammatory condition and quantifying local inflammatory activity in a body fluid.Type: ApplicationFiled: November 10, 2014Publication date: July 23, 2015Applicants: DUKE UNIVERSITY MEDICAL CENTER, NEW YORK UNIVERSITYInventors: Philip A. BAND, Hans-Georg WISNIEWSKI, Virginia BYERS KRAUS
-
Patent number: 8980284Abstract: This invention relates to isolated Clostridium botulinum propeptides and neurotoxins, isolated nucleic acid molecules encoding Clostridium botulinum propeptides and neurotoxins, methods of expression, treatment methods, and methods of detecting neurotoxin trafficking. The isolated Clostridium botulinum propeptides have a light chain region; a heavy chain region, where the light and heavy chain regions are linked by a disulfide bond; an intermediate region connecting the light and heavy chain regions and comprising a highly specific protease cleavage site; and an S6 peptide sequence according to SEQ ID NO:2 positioned upstream from, but not attached directly to, the N-terminus of the neurotoxin propeptide at the light chain region to enable site specific attachment of cargo.Type: GrantFiled: January 25, 2011Date of Patent: March 17, 2015Assignee: New York UniversityInventors: Konstantin Ichtchenko, Philip A. Band
-
Patent number: 8883427Abstract: This invention relates to a method of predicting progression of an inflammatory condition in a subject, which involves providing a medium comprising hyaluronan or a fragment thereof; contacting the medium with a fluid sample from a subject with an inflammatory condition, where the fluid sample comprises proteins or proteoglycans and a transfer agent; incubating the fluid sample with the medium under conditions effective for the transfer agent in the fluid sample to mediate transfer of heavy chains from the proteins or proteoglycans to the hyaluronan or a fragment thereof to form a complex; detecting, using an antibody, occurrence levels of the complex; and comparing occurrence levels of the complex from said detecting to a reference standard to predict progression of an inflammatory condition in the subject. Also disclosed are methods of tailoring treatment of an inflammatory condition and quantifying local inflammatory activity in a body fluid.Type: GrantFiled: June 29, 2011Date of Patent: November 11, 2014Assignees: New York University, Duke University Medical CenterInventors: Philip A. Band, Hans-Georg Wisniewski, Virginia Byers Kraus
-
Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof
Patent number: 8865186Abstract: The present invention relates to an isolated Clostridial neurotoxin propeptide having a light chain region, a heavy chain region, where the light and heavy chain regions are linked by a disulfide bond, and an intermediate region connecting the light and heavy chain regions. An isolated nucleic acid molecule encoding a Clostridial neurotoxin propeptide is also disclosed. Also disclosed is an isolated, physiologically active Clostridial neurotoxin produced by cleaving a Clostridial neurotoxin propeptide, a vaccine or antidote thereof, and methods of immunizing against or treating for toxic effects of Clostridial neurotoxins. Methods of expressing recombinant physiologically active Clostridial neurotoxins are also disclosed. Also disclosed is a chimeric protein having a heavy chain region of a Clostridial neurotoxin and a protein with therapeutic functionality. A treatment method is also disclosed.Type: GrantFiled: October 3, 2011Date of Patent: October 21, 2014Assignee: New York UniversityInventors: Konstantin Ichtchenko, Philip A. Band -
Publication number: 20140212456Abstract: The present invention relates to a treatment method. This method involves contacting a subject with an isolated, physiologically active, atoxic derivative of a Clostridial neurotoxin. Contacting is carried out to treat the subject. The derivative of a Clostridial neurotoxin does not possess a cargo attachment peptide sequence at its N-terminus.Type: ApplicationFiled: January 28, 2014Publication date: July 31, 2014Applicant: NEW YORK UNIVERSITYInventors: Edwin J. Vazquez-Cintron, Konstantin Ichtchenko, Philip A. Band
-
Biocompatible materials containing stable complexes of TSG-6 and hyaluronan and method of using same
Patent number: 8420601Abstract: The present invention provides a biocompatible material in the form of a water insoluble cross-linked gel, which contains a stable complex of TNF-stimulated gene 6 protein (TSG-6) and hyaluronan.Type: GrantFiled: November 18, 2011Date of Patent: April 16, 2013Assignees: New York University, Polytechnic Institute of NYUInventors: Hans-Georg Wisniewski, Mary K. Cowman, Philip Band -
BIOCOMPATIBLE MATERIALS CONTAINING STABLE COMPLEXES OF TSG-6 AND HYALURONAN AND METHOD OF USING SAME
Publication number: 20120064150Abstract: The present invention provides a biocompatible material in the form of a solid, a water insoluble cross-linked gel or a liposome, which contains a stable comples of TNF-stimulated gene 6 protein (TSG-6) and hyaluronan.Type: ApplicationFiled: November 18, 2011Publication date: March 15, 2012Applicant: NEW YORK UNIVERSITY POLYTECHNIC INSTITUTE OF NYUInventors: Hans-Georg WISNIEWSKI, Mary K. Cowman, Philip Band -
Publication number: 20120028369Abstract: This invention relates to a method of predicting progression of an inflammatory condition in a subject, which involves providing a medium comprising hyaluronan or a fragment thereof; contacting the medium with a fluid sample from a subject with an inflammatory condition, where the fluid sample comprises proteins or proteoglycans and a transfer agent; incubating the fluid sample with the medium under conditions effective for the transfer agent in the fluid sample to mediate transfer of heavy chains from the proteins or proteoglycans to the hyaluronan or a fragment thereof to form a complex; detecting, using an antibody, occurrence levels of the complex; and comparing occurrence levels of the complex from said detecting to a reference standard to predict progression of an inflammatory condition in the subject. Also disclosed are methods of tailoring treatment of an inflammatory condition and quantifying local inflammatory activity in a body fluid.Type: ApplicationFiled: June 29, 2011Publication date: February 2, 2012Applicants: DUKE UNIVERSITY MEDICAL CENTER, NEW YORK UNIVERSITYInventors: Philip A. BAND, Hans-Georg WISNIEWSKI, Virginia Byers Kraus
-
GENETICALLY ENGINEERED CLOSTRIDIAL GENES, PROTEINS ENCODED BY THE ENGINEERED GENES, AND USES THEREOF
Publication number: 20120021002Abstract: The present invention relates to an isolated Clostridial neurotoxin propeptide having a light chain region, a heavy chain region, where the light and heavy chain regions are linked by a disulfide bond, and an intermediate region connecting the light and heavy chain regions. An isolated nucleic acid molecule encoding a Clostridial neurotoxin propeptide is also disclosed. Also disclosed is an isolated, physiologically active Clostridial neurotoxin produced by cleaving a Clostridial neurotoxin propeptide, a vaccine or antidote thereof, and methods of immunizing against or treating for toxic effects of Clostridial neurotoxins. Methods of expressing recombinant physiologically active Clostridial neurotoxins are also disclosed. Also disclosed is a chimeric protein having a heavy chain region of a Clostridial neurotoxin and a protein with therapeutic functionality. A treatment method is also disclosed.Type: ApplicationFiled: October 3, 2011Publication date: January 26, 2012Applicant: NEW YORK UNIVERSITYInventors: Konstantin Ichtchenko, Philip A. Band -
Patent number: 8093365Abstract: The present invention provides a biocompatible material in the form of a solid, a water insoluble cross-linked gel or a liposome, which contains a stable complexes of TNF-stimulated gene protein (TSG-6) and hyaluronan.Type: GrantFiled: February 17, 2009Date of Patent: January 10, 2012Assignees: New York University, Polytechnic Institute of NYUInventors: Hans-Georg Wisniewski, Mary K. Cowman, Philip Band
-
Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof
Patent number: 8044188Abstract: The present invention relates to an isolated Clostridial neurotoxin propeptide having a light chain region, a heavy chain region, where the light and heavy chain regions are linked by a disulfide bond, and an intermediate region connecting the light and heavy chain regions. An isolated nucleic acid molecule encoding a Clostridial neurotoxin propeptide is also disclosed. Also disclosed is an isolated, physiologically active Clostridial neurotoxin produced by cleaving a Clostridial neurotoxin propeptide, a vaccine or antidote thereof, and methods of immunizing against or treating for toxic effects of Clostridial neurotoxins. Methods of expressing recombinant physiologically active Clostridial neurotoxins are also disclosed. Also disclosed is a chimeric protein having a heavy chain region of a Clostridial neurotoxin and a protein with therapeutic functionality. A treatment method is also disclosed.Type: GrantFiled: April 19, 2010Date of Patent: October 25, 2011Assignee: New York UniversityInventors: Konstantin Ichtchenko, Philip A. Band -
Publication number: 20110206616Abstract: This invention relates to isolated Clostridium botulinum propeptides and neurotoxins, isolated nucleic acid molecules encoding Clostridium botulinum propeptides and neurotoxins, methods of expression, treatment methods, and methods of detecting neurotoxin trafficking. The isolated Clostridium botulinum propeptides have a light chain region; a heavy chain region, where the light and heavy chain regions are linked by a disulfide bond; an intermediate region connecting the light and heavy chain regions and comprising a highly specific protease cleavage site; and an S6 peptide sequence according to SEQ ID NO:2 positioned upstream from, but not attached directly to, the N-terminus of the neurotoxin propeptide at the light chain region to enable site specific attachment of cargo.Type: ApplicationFiled: January 25, 2011Publication date: August 25, 2011Applicant: NEW YORK UNIVERSITYInventors: Konstantin ICHTCHENKO, Philip A. BAND
-
Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof
Patent number: 7785606Abstract: The present invention relates to an isolated Clostridial neurotoxin propeptide having a light chain region, a heavy chain region, where the light and heavy chain regions are linked by a disulfide bond, and an intermediate region connecting the light and heavy chain regions. An isolated nucleic acid molecule encoding a Clostridial neurotoxin propeptide is also disclosed. Also disclosed is an isolated, physiologically active Clostridial neurotoxin produced by cleaving a Clostridial neurotoxin propeptide, a vaccine or antidote thereof, and methods of immunizing against or treating for toxic effects of Clostridial neurotoxins. Methods of expressing recombinant physiologically active Clostridial neurotoxins are also disclosed. Also disclosed is a chimeric protein having a heavy chain region of a Clostridial neurotoxin and a protein with therapeutic functionality. A treatment method is also disclosed.Type: GrantFiled: November 22, 2005Date of Patent: August 31, 2010Assignee: New York UniversityInventors: Konstantin Ichtchenko, Philip A. Band -
GENETICALLY ENGINEERED CLOSTRIDIAL GENES, PROTEINS ENCODED BY THE ENGINEERED GENES, AND USES THEREOF
Publication number: 20100196421Abstract: The present invention relates to an isolated Clostridial neurotoxin propeptide having a light chain region, a heavy chain region, where the light and heavy chain regions are linked by a disulfide bond, and an intermediate region connecting the light and heavy chain regions. An isolated nucleic acid molecule encoding a Clostridial neurotoxin propeptide is also disclosed. Also disclosed is an isolated, physiologically active Clostridial neurotoxin produced by cleaving a Clostridial neurotoxin propeptide, a vaccine or antidote thereof, and methods of immunizing against or treating for toxic effects of Clostridial neurotoxins. Methods of expressing recombinant physiologically active Clostridial neurotoxins are also disclosed. Also disclosed is a chimeric protein having a heavy chain region of a Clostridial neurotoxin and a protein with therapeutic functionality. A treatment method is also disclosed.Type: ApplicationFiled: April 19, 2010Publication date: August 5, 2010Applicant: NEW YORK UNIVERSITYInventors: Konstantin Ichtchenko, Philip A. Band